Uncovering the white place: whitewashing at work

Recent work exploring the racialization of place tends to focus on the racialization of marginalized group space. This paper shifts attention toward the racialization of dominant group space, namely, the creation and maintenance of white places. Using the case study of the software workplace, I argue that white places are formed through a process of whitewashing, which simultaneously denies race and superimposes white culture. Whitewashing wields language and invisibility to deny race and promote a particular kind of multiculturalism, while cloaking the workplace in a culture of informality and business politics. The whitewashed workplace, like a whitewashed wall, is seen as colorless rather than white as white culture becomes universalized as high-tech culture. I draw my findings from in-depth interviews on workplace satisfaction, relationships, culture and diversity with black, Asian and white employees in Seattle-area software firms

Adding Racial Equity to the Menu: An Equity Toolkit for Restaurant Employers

This Racial Equity Toolkit provides restaurant management with practical resources for assessing, planning, and implementing steps toward racial equity at your business. There is no step too small: every action you take helps your business thrive and fosters stronger local relationships with your workers and consumers.This toolkit combines the expertise of three national organizations: Restaurant Opportunities Centers United (ROC United), Race Forward, and the Center for Social Inclusion. Collectively, these organizations have decades of experience in restaurant-standards innovation and racial-equity consulting. To ensure this tool is useful, realistic, and accessible for real-life people in the industry, we partnered with two respected fine dining and casual dining restaurants in the San Francisco Bay Area: Alta (San Francisco) and Homeroom (Oakland)

Removing Barriers to Breastfeeding: A Structural Race Analysis of First Food

This report highlights structural barriers that women face during pregnancy, at the hospital, and in their first weeks and months at home after the baby is born -- including access to Baby-Friendly hospitals and certified lactation consultants, which are often lacking in neighborhoods of color. Our hope is that this foundational analysis gives a baseline to think more deeply about the barriers created by both policy and practice, and gives people the tools to take action to ensure that all women have the choice to breastfeed

Safety and Efficacy of a Bioabsorbable Polymer-Coated, Everolimus-Eluting Coronary Stent in Patients with Diabetes: the EVOLVE II Diabetes Substudy.

AIMS Bioabsorbable-polymer drug-eluting stents (DES) may reduce inflammation and delayed healing associated with some permanent polymer-coated DES. Whether late clinical outcomes are improved, particularly among patients with medically-treated diabetes, is unknown. METHODS AND RESULTS SYNERGY is a thin-strut, platinum chromium everolimus-eluting stent with an ultrathin bioabsorbable poly (DL-lactide-co-glycolide) abluminal polymer. The EVOLVE II randomized, controlled trial proved noninferiority of SYNERGY versus the PROMUS Element Plus stent for 1-year target lesion failure (TLF: ischemia- driven target lesion revascularization [ID-TLR], target-vessel myocardial infarction [TVMI], or cardiac death). The prespecified EVOLVE II Diabetes Substudy prospectively pooled randomized patients with diabetes (N=263) with a sequential single-arm diabetic cohort (n=203). The substudy primary endpoint was 1-year TLF compared with a prespecified performance goal (14.5%). The primary endpoint occurred in 7.5% of SYNERGY-treated patients with diabetes, significantly less than the performance goal (P<0.0001). The 2-year rate of TLF was 11.2% (cardiac death 1.5%, TVMI 6.4%, ID-TLR 6.8%) and definite/probable stent thrombosis occurred in 1.1% of patients. CONCLUSIONS The EVOLVE II Diabetes substudy demonstrates efficacy and safety of the SYNERGY stent in patients with medically-treated diabetes

Arterial endothelial function in a porcine model of early stage atherosclerotic vascular disease

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States and is projected to become the leading cause of mortality in the world. Atherosclerosis is the most important single factor contributing to this disease burden. In this study, we characterize relationships between endothelial dysfunction and vascular disease in an animal model of diet-induced, early-stage atherosclerotic vascular disease. We tested the hypothesis that hypercholesterolaemia induces vascular disease and impairs endothelium-dependent relaxation (EDR) in conduit arteries of adult male Yucatan pigs. Pigs were fed a normal fat (NF) or high fat cholesterol (HFC) diet for 20–24 weeks. Results indicate that, while the HFC diet did not alter EDR in femoral or brachial arteries, EDR was significantly decreased in both carotid and coronary arteries. Sudanophilic fatty streaks were significantly present in the abdominal aorta and common carotid artery. Histopathology revealed increased intima-media thickness (IMT) and foam cell accumulation in Stary Stage I–III lesions in the abdominal aorta, common carotid artery and femoral arteries. In the coronary arteries, the accumulation of foam cells in Stary Stage I and II lesions resulted in a trend for increased IMT. There was no evidence of vascular disease in the brachial arteries. These results indicate that early stages of CVD (Stary Stage I–III) precede decreases in EDR induced by HFC diet, because femoral arteries exhibited foam cell accumulation and an increased IMT but no change in endothelial function